Releases

ReleasesFundación GEP2020-10-28T11:50:37-03:00

COVID-19: Good intentions do not guarantee vaccines and treatments for everyone

Sovereignty: the best medicine against COVID-19

Compulsory licenses to guarantee access to medical technologies

Remdesivir in Argentina: new patent opposition filed by Fundación GEP intends to stop Gilead’s abusive behaviour

Argentina: Fundación GEP opposed Gilead´s patent application on remdesivir

COVID19- South America: Gilead block access to coronavirus treatment for 440 million people

RedLAM in Geneva: A week of actions against the Corporate Power and to reclaim Peoples Sovereignty

WhatsApp Image 2019-07-01 at 17.59.58

Fundación GEP filed patent opposition on Hepatitis C treatment

Argentina: elimination of the Ministry of Health threatens PLHIV lives

Argentina: Stockouts of ARVs threatens continuation of HIV treatments

Hepatitis C: In Argentina INPI rejected a key patent on Sofosbuvir

The power of communities against monopolies

Diseño sin título-8

Eu-Mercosur Bi-Regional Association Agreement: impact of the intellectual property chapter on public procurement of medicines in Argentina

Gilead forced to withdraw Truvada® patent application in Argentina

Argentina’s Patent Office signs bilateral agreement with the US harming public health and national laws

GEP filed new opposition to patent request for Hepatitis C drug in Argentina

International Congress on Access to Medicines and Human Rights’ Full Schedule

International Congress on Access to Medicines, Medical Technologies and Human Rights

Agregar un título

Big Pharma’s court cases in Brazil & Argentina threaten national laws considered important public health safeguards in the UN HLP report